Abstract | BACKGROUND: METHODS: This Phase 1 study evaluated efficacy/safety of inhaled single-dose MK-5475, an investigational, small-molecule stimulator of soluble guanylate cyclase designed for inhaled delivery via a dry-powder inhaler device, in participants with PAH (Clinicaltrials.gov: NCT03744637). Eligible participants were 18-70 years of age; body mass index ≤35 kg/m2; diagnosis of PAH (Group 1 pulmonary hypertension). In Part 1, participants received double-blind MK-5475 or placebo for safety assessment (primary outcome). In Part 2, 4 panels participated in ≤3 open-label periods. Part 2/Period 1 assessed safety/tolerability. Part 2/Periods 2 and 3, respectively, involved functional respiratory imaging for measuring pulmonary blood volume (secondary outcome) and right heart catheterization for measuring pulmonary vascular resistance (primary outcome). RESULTS: MK-5475 was generally well tolerated without systemic side effects on blood pressure or heart rate up to 24 h post dose. With respect to the primary pharmacodynamic outcome, mean reductions in pulmonary vascular resistance ranged from 21% to 30% across 120 μg and 360 μg doses. CONCLUSIONS: Treatment with inhaled single-dose MK-5475 showed rapid and sustained reductions in pulmonary vascular resistance and increases in pulmonary blood volume. MK-5475 was generally well tolerated versus placebo without vasodilatory systemic side effects. The promising pulmonary selectivity and favorable safety/tolerability profile of MK-5475 seen in this study of adult participants with PAH lays the foundation for further clinical development.
|
Authors | Ednan K Bajwa, Dawn Cislak, John Palcza, Hwa-Ping Feng, Eric J Messina, Tom Reynders, Jean-François Denef, Vasile Corcea, Eseng Lai, S Aubrey Stoch |
Journal | Respiratory medicine
(Respir Med)
Vol. 206
Pg. 107065
(01 2023)
ISSN: 1532-3064 [Electronic] England |
PMID | 36521262
(Publication Type: Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Published by Elsevier Ltd.. All rights reserved. |
Chemical References |
- Soluble Guanylyl Cyclase
- Vasodilator Agents
|
Topics |
- Adult
- Humans
- Pulmonary Arterial Hypertension
(drug therapy)
- Soluble Guanylyl Cyclase
(administration & dosage)
- Vasodilator Agents
(therapeutic use)
- Adolescent
- Young Adult
- Middle Aged
- Aged
|